Clinical Trial Breakthrough: Testing of NBD1 Stabilizers SION-719 and SION-451 for Cystic Fibrosis Transmembrane Conductance Regulator

Clinical Trial Breakthrough: Testing of NBD1 Stabilizers SION-719 and SION-451 for Cystic Fibrosis Transmembrane Conductance Regulator The landscape of cystic fibrosis (CF) treatment is on the cusp of a significant breakthrough with the initiation of two phase 1 clinical trials by Sionna Therapeutics. The pharmaceutical company has begun dosing healthy volunteers in Australia to test […]